Myocardial Infarction (mi) Or Acute Myocardial Infarction (ami), Commonly Known As A Heart Attack, Is The Interruption Of Blood Supply To A Part Of The Heart, Causing Heart Cells To Die. This Is Most Commonly Due To Blockage Of A Coronary Artery. The Blockage Is An Unstable Collection Of Lipids (fatty Acids) And White Blood Cells In The Wall Of An Artery And Results In The Restriction In Blood Supply And Oxygen Shortage. If Left Untreated For A Sufficient Period Of Time, Can Cause Damage Of Heart Muscle Tissue (myocardium) And Can Prove Fatal. Important Risk Factors Are Previous Cardiovascular Disease, Older Age, Smoking, High Blood Levels Of Certain Lipids (triglycerides, Low-density Lipoprotein) And Low Levels Of High Density Lipoprotein (hdl), Diabetes, High Blood Pressure, Obesity, Chronic Kidney Disease, Heart Failure, Excessive Alcohol Consumption, The Abuse Of Certain Drugs And Chronic High Stress Levels. Myocardial Infarction Is A Common Presentation Of Ischemic Heart Disease. The Who Estimated In 2002, That 12.6 Percent Of Worldwide Deaths Were From Ischemic Heart Disease. It Is The Leading Cause Of Death In Developed Countries, And Third To Aids And Lower Respiratory Infections In Developing Countries. Stem Cells Are Believed To Work By Two Major Mechanisms. Infusion Of Ex Vivo Cultivated Endothelial Progenitor Cells (epcs) May Boost Capillary Density, Neovascularization Of Ischemic Tissue, Significantly Improved Blood Flow, Cardiac Function And Reduced Left Ventricular Scarring. In Addition, Transplantation Of Ex Vivo Cultivated Endothelial Progenitor Cells (epcs) Can Significantly Improved Coronary Flow Reserve And Left Ventricular Function In Patients With Acute Myocardial Infarction. Thus Administration Of Endothelial Progenitor Cells (epcs) Is A Promising Therapy For Post-infarction Cardiac Repair. Regeneration In Vessel Has Made Endothelial Progenitor Cells A Suitable Candidate For Therapeutic Applications Aiming At Tissue Revascularization
